MMs who get judged on the quality of the investments they make probably don't want to show this one on their books at report time. Also, tax loss selling to offset gains just about anywhere else in the US market (see SPY and QQQ) is likely to drive the share price lower as well.
"So, just who is going to do any of the official ousting of who?"
A consortium of major share holders. You're right to state that the BOD is useless. They do what Shrotriya tells them to do.
"Lowest compensation of all his peers".
May still be overpaid. After all the false starts and SNAFUS the burden of proof is on him.
I hear them talking about all the wonderful things to come. I'd like to see them deliver as promised - as specified, correctly and on time. So far there's a lot of sizzle and no steak. This gets old. It's time for management to deliver or get the hell out. I hope the large bag holders are coming to this conclusion. It really is time.
The company's aloofness in the face of this endless share price erosion is infuriating.
"Who is flush with cash?"
They are - unless they expect Fusilev revenue to dry up.
"they are NOT going to waste cash on manipulating PPS when they have block busters to fund"
That seems to be their position as well. I don't call it manipulation though. I prefer enhancing shareholder value - if the current price is truly too low for the value represented by the share prices.
" Do you honestly think they are working AGAINST their 25% ownership?"
No. Of course not. But I want them to give some clarity of what they are doing. Why would you not buy back a these levels when you are flush with cash. I hear the bones rattling; I want to see the skeleton (if there is one).
and no action from the company even at these prices.
Either they want to preserve cash in the event the Fusilev patent challenge goes against them, or
Belodaq revenue is not expected be enough to make up for a possible loss of Fusilev revenue, or
they expect the share price to drop even lower.
I don't like any of these alternatives. Wish someone at Spectrum would wake up long enough to explain what the #$%@ they are up to. Clearly these people have forgotten that they work for the share holders - unless of course the major share holders get information that we don't (wouldn't that be illegal?).
Hint taken. No joy. Tried to listen to the early 2013 web casts on the SPPIRX site (to May of 2013). They are no longer available. Oh well...
Thanks for your answers, Tartiaboy and Antihama. It looks from your posts like the possibilities are wide open for any outcome. One relevant tidbit from Joe Turgeon's first corporate presentation when he was still in charge of marketing: he said that the results from the multi instillation trial were "through the roof" (early days then of course).
I obviously don't know if that just the kind of hype one expects from a salesman or if there was more to it than that. It's intriguing though.
I'm missing something here, maybe you can help. Years ago there was an assertion that there are about 60,000 new cases of bladder cancer each year. Treatment cost was estimated at $30,000 per patient. I can't quote the source of these numbers anymore, can you confirm or correct them?
Assuming the numbers are correct... Since there is no alternative treatment to take Apaziqoune's place the size of the market is $1.8 billion. Seems to me that peak sales could reach north of a billion. What's off?
My personal favorite is solid growth in Beleodaq revenue. It should make the Fusilev drama a side show at last. Finally; basta; finite; bye bye...
are you basing that on a favorable Fusilev decision, SPI data at ASCO, or Beleodaq revenue? Which one do you think is the main force to fuel a turn around?